Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Portal Hypertension SIG: Mechanisms of Regression of Portal Hypertension

    Contains 7 Component(s) Recorded On: 11/09/2018

    AASLD's Portal Hypertension SIG: Mechanisms of Regression of Portal Hypertension presented at The Liver Meeting® 2018.

    There has been no new drug class in the treatment of portal hypertension in over 25 years. But recent advancements in our understanding of the pathophysiology of portal hypertension and its potential regression have informed development of oninvasive biomarkers and revealed exciting new targets for therapy. This program will discuss key developments in the basic biology of portal hypertension and how this knowledge is being applied to develop novel biomarkers and therapeutic approaches for portal hypertension.

    Jonathan Fallowfield

    Jordi Gracia-Sancho

    Annalisa Berzigotti

    Ramon Bataller

    Guadalupe Garcia-Tsao

    Dr. Garcia-Tsao is Professor of Medicine, Chief of Digestive Diseases and Program Director of the Hepatitis C Resource Center at Veteran’s Administration-Connecticut Healthcare System, as well as Director of Clinical and Translational Core at Yale Liver Center. She is a past president of AASLD. She received her M.D. and training at Universidad Nacional Autónoma de Mexico. Her primary research focus is on clinical research which focuses on cirrhosis and its complications, and she also is involved in the study of bacterial infections in cirrhosis, a complication that is often overlooked.

  • Hepatotoxicity SIG: Herbal and Dietary Supplement Induced Liver Injury: Defining the Future

    Contains 9 Component(s) Recorded On: 11/09/2018

    AASLD's Hepatotoxicity SIG: Herbal and Dietary Supplement Induced Liver Injury: Defining the Future presented at The Liver Meeting® 2018.

    This program will focus on liver injury due to herbal and dietary supplements. The program will begin with a description of a realworld case of liver injury due to OxyElite Pro, which highlights the challenges faced by diagnosticians and researchers in establishing causation for hepatotoxicity due to herbal and dietary supplements. The program will also review the role of the FDA, CDC and chemists, including scientists with the National Center for Natural Products Research, at the University of Mississippi, who perform product chemical analyses.

    Victor J. Navarro

    Raul Andrade

    Robert J. Fontana

    Ikhlas Khan

    Melissa Viray

    Monique Salter

    Adrian Reuben

    Dr. Reuben is Professor of Medicine Emeritus (January 2015) at the Medical University of South Carolina, in Charleston SC, where he directed the Liver Program that he created there in 1993. Dr. Reuben was born, raised and educated in London, UK, where he obtained his medical degree, completed his Residency and Fellowship in Gastroenterology (Guys Hospital, London) before completing a scholarship in the Liver Study Unit at Yale School of Medicine. He was appointed to the faculty at Yale (1981-1993) before moving to MUSC to establish a Liver Service and enhance the then fledgling Liver Transplant program.

    His continuing research interests focus on Acute Liver Failure, Coagulopathy in Liver Disease, Complications of Cirrhosis, and Drug Hepatotoxicity - in which he has co-authored many original articles.

    In addition to all aspects of clinical hepatology, he has considerable experience in liver transplantation, portal hypertension and hepatocellular carcinoma - about which he edited two issue in Clinics in Liver Disease. Until 2006 he also had a laboratory-based career that focused initially on biliary lipid secretion, and later on hepatic fibrogenesis. He has published over 100 peer-reviewed articles, editorials, case reports, book chapters and 44 essays on Hepatology history in the successful Landmarks in Hepatology series. Currently he is editing a new series of more than 50 essays on the History of Hepatology by renowned experts worldwide, to be published in the AASLD online journal Clinical Liver Disease (Editor: Nancy Reau, Rush Medical Center, Chicago IL).

    Reuben has presented original research papers at national and international meetings as well as teaching in postgraduate courses and workshops, and presenting invited lectures in the United States, Europe, the UK, and Asia. He served on several committees of the American Association for the Study of Liver Disease, including the Ethics Committee of which he was the Chair three years ago, and now he is the Chair-elect of the AASLD Hepatotoxicity Special Interest Group (SIG). Despite retirement from clinical practice, Adrian Reuben remains active in lecturing, collaborating in research projects, reviewing manuscripts, writing chapters and reviews as well as publishing original research articles. His interest in drug hepatotoxicity stems from his medical student days, when he obtained a bachelor degree in Pharmacology, and is exemplified by the publication of an original article in Hepatology, on Acute Liver Failure due to Drug-Induced Liver Injury, on behalf of the United States Acute Liver Failure Study Group (ALFSG), for which he was also the first author of an overview of 16 years’ experience in Acute Liver Failure.

    Finally, Reuben is to be the recipient of the 2019 AASLD Distinguished Service Award.

  • Liver Cell Biology in Hepatic Diseases SIG: Organelle Trafficking and Lipid Droplets Biology

    Contains 9 Component(s) Recorded On: 11/09/2018

    AASLD's Liver Cell Biology in Hepatic Diseases SIG: Organelle Trafficking and Lipid Droplets Biology presented at The Liver Meeting® 2018.

    This program discusses different, yet related, basic molecular mechanisms of hepatic damage and inflammation fundamental for the development of various types of liver diseases. Discussions will cover the mechanisms for vesicle formation and  endocytosis, how secretion of exosomes occurs upon inflammasome activation, the impact of immune cell-derived vesicles on fibrosis and the process of collagen secretion. The second part of the program focuses on novel signaling pathways  involved in disease resolution.

    This program will provide an excellent opportunity to learn the basic molecular mechanisms of hepatic damage and inflammation fundamental for the development of various types of liver diseases.

    Mark McNiven

    Ann Wozniak

    Yasuko Iwakiri

    Xin Chen

    Z. Gordon Jiang

    Richard Green

  • Acute on Chronic Liver Failure SIG: The Role of Infection in the Development of ACLF

    Contains 8 Component(s) Recorded On: 11/09/2018

    AASLD's Acute on Chronic Liver Failure SIG: The Role of Infection in the Development of ACLF presented at The Liver Meeting® 2018.

    Bacterial infections are common in patients with advanced cirrhosis — partly related to altered microbiota, partly related to increased bacterial translocation across the gut wall and partly related to compromised immune function of these patients. When bacterial infection occurs, the heightened inflammatory reaction that follows predisposes these patients to altered hemodynamics and direct tissue damage. Therefore, these patients are prone to develop organ failure and ACLF when bacterial infection occurs. This program discusses recent findings on how altered microbiota and inflammation are involved in the pathogenesis of organ failure and ACLF in cirrhosis. Approach to treatment of various organ failures as well as preventive measures will be discussed.

    Jasmohan S. Bajaj

    Gyongyi Szabo

    Salvatore Piano

    Florence Wong

    Guadalupe Garcia-Tsao

    Dr. Garcia-Tsao is Professor of Medicine, Chief of Digestive Diseases and Program Director of the Hepatitis C Resource Center at Veteran’s Administration-Connecticut Healthcare System, as well as Director of Clinical and Translational Core at Yale Liver Center. She is a past president of AASLD. She received her M.D. and training at Universidad Nacional Autónoma de Mexico. Her primary research focus is on clinical research which focuses on cirrhosis and its complications, and she also is involved in the study of bacterial infections in cirrhosis, a complication that is often overlooked.

  • Best Practices for Managing Cardiovascular Risk After Liver Transplantation

    Contains 2 Component(s) Recorded On: 10/31/2018

    Webinar hosted by the Cardiopulmonary Affinity group on October 31, 2018.

    The overall objective of this activity is to address the epidemiology, risk factors and key challenges in the evaluation and management of cardiovascular disease risk factors in liver transplant recipients. In particular, we will discuss practical approaches and pharmacologic considerations in the prevention and management of hypertension, dyslipidemia and diabetes in liver transplant recipients.  We will utilize a live webinar format that will be recorded for on demand viewing on LiverLearning®.

    Manhal Izzy (Moderator)

    Dr. Manhal Izzy is a transplant hepatologist and an assistant professor at Vanderbilt University School of Medicine. He is a member of the educational committee of the International Liver Transplantation Society (ILTS). His research focuses on cardiovascular outcomes in patients with liver disease.

    Yogish Kudva

    Yogish Kudva is an adult Endocrinologist focused on clinical research involving patients with Type 1 diabetes.  He has been involved in randomized, trials of T1D since 2000, Insulin pump trials since 2006 and artificial pancreas since 2009. His clinical and research work includes Beta Cell transplantation for Diabetes.  His work is been funded by the NIH, JDRF and The Helmsley Trust. 

    Lisa VanWagner

    Dr. Lisa VanWagner is an Assistant Professor of Medicine and Preventive Medicine in the Division Gastroenterology & Hepatology at Northwestern University Feinberg School of Medicine in Chicago, Illinois.  She is board certified in Transplant Hepatology.  Her laboratory utilizes human population-based approaches, large electronic health record data analysis and health services research methods to define and characterize cardiovascular disease risk prediction, prevention and treatment approaches in patients with chronic liver disease.  Her research group developed the first simple scoring model (CAR-OLT score) — accessible via web or smartphone apps — which enables healthcare providers, caregivers and patients to estimate 1-year risk for cardiovascular complications after liver transplantation.

  • HBV - Update on the Guidelines and Controversies in Management

    Contains 1 Component(s) Recorded On: 10/24/2018

    Webinar hosted by the Hepatitis B Special Interest Group October 24, 2018.

    This webinar focuses on reviewing the highlights of the revised AASLD Clinical Practice Guidelines for HBV infection in the first talk.  The second presentation addresses a key area of controversy, namely the role of antiviral therapy in patients during the immunotolerant phase of chronic HBV infection.

    Marc G. Ghany (Moderator)

    Dr. Ghany is an Investigator at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases, and at Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda. He is member the Physician Consortium for Practice Improvement for Hepatitis C, which is jointly sponsored by the American Medical Association and AASLD and serves on the hepatitis C Guidance panel which is jointly sponsored by the AASLD and Infectious Diseases Society of America. His work has been honored with the Regal Award for Excellence in Gastrointestinal and Liver Disease and with several NIDDK service awards including the Director’s Award. He received his M.B. and B.Ch. from the Royal College of Surgeon’s, Dublin, and Master of Health Sciences in Clinical Research, Duke University. He completed residency at the Hospital of Saint Raphael, New Haven, Connecticut, a fellowship in gastroenterology at Tulane University, New Orleans, and a clinical fellowship at the Liver Diseases Section, NIDDK. Dr. Ghany’s focus is on translational research to improve the care and treatment outcomes of patients with chronic viral hepatitis. 

     

    Norah A. Terrault

    Dr. Norah Terrault is the Professor of Medicine and the Director of the Viral Hepatitis Center at the University of California San Francisco. She is recognized nationally and internationally for her work related to viral hepatitis, especially in the setting of liver transplantation.  She has authored more than 290 original articles, reviews and book chapters on viral hepatitis, including the recent AASLD Hepatitis B Treatment Guidelines. She has served as associate editor for Hepatology, is current Associate Editor for Hepatology Communications and a member of the AASLD HCV Guidance Committee. She is an investigator on several NIH-funded clinical studies in hepatitis B and C, as well as NASH and is an investigator on several ongoing clinical trials of novel therapies for patients with chronic liver diseases.

     

     

    Kosh Aggarwal

    Dr. Kosh Agarwal is a Consultant Hepatologist and Transplant Physician at the Institute of Liver Studies, King’s College Hospital. Dr Agarwal is the Lead for the Kings Viral Hepatitis Service, the largest treatment centre for viral hepatitis in the UK. In 1991 Dr Agarwal graduated from Newcastle University and his postgraduate training was undertaken in Newcastle with the majority of his clinical and research training at the Regional Liver and Transplant Unit. Prior to his appointment at King’s, Dr Agarwal was a consultant and honorary senior lecturer at the Regional Liver and Transplant Unit in Newcastle. He also spent a year at the Division of Liver Diseases, Mount Sinai, New York, USA. Dr Agarwal is an investigator for several ongoing studies evaluating the safety and efficacy of various antiviral treatment regimens for chronic Hepatitis B and C. He is a member of the EASL, AASLD, BASL, & ILTS.

  • 2018 Transplant Hepatology Board Review Course

    Contains 36 Component(s), Includes Credits Recorded On: 08/19/2018

    This course will help prepare physicians for the ABIM and ABP certification and MOC exam in transplant hepatology and pediatric transplant hepatology as it reflects the updated ABIM/ABP Transplant Hepatology Certification Exam blueprint.

    This course will help prepare physicians for the American Board of Internal Medicine (ABIM) and American Board of Pediatrics (ABP) certification and maintenance of certification (MOC) exam in transplant hepatology and pediatric transplant hepatology as it reflects the updated ABIM/ABP Transplant Hepatology Certification Exam blueprint. High yield clinical topics will be presented by leaders in the field of hepatology and transplant medicine. Designed for ABIM/ABP Transplant Hepatology exam preparation, the course also provides a comprehensive review of up-to-date management of liver transplant patients.

    Online Course Pricing:

    • Member — $325
    • Trainee and Associate Member — $185
    • Nonmember — $540
    • Nonmember Trainee / Associate — $235
    • Industry — $775

    Core Competencies

    • Patient care and Procedural Skills
    • Medical knowledge
    • Practice-based learning and improvement
    • Patient-centered care
    • Evidence-based practice
    • Quality improvement
    • Values/Ethics for inter-professional practice

    Program Chairs:

    • K. Gautham Reddy, MD, FAASLD
    • Oren K. Fix, MD, MSc, FAASLD
    • Laura M. Kulik, MD

    Components

    29 online interactive recorded sessions, 20-30 minutes in length
    Post-activity quiz for each session

    Release Date: September 14, 2018
    Expiration Date: September 13, 2020

    Copyright: All faculty in this activity have given their permission for publication OR ©2018 AASLD

    K. Gautham Reddy (Moderator)

    Oren K. Fix (Moderator)

    Laura M. Kulik (Moderator)

    Michael R. Lucey

    Julie Heimbach

    Michael R. Charlton

    Marina G. Silveira

    Jennifer C. Lai

    Dr. Lai is a transplant hepatologist, on faculty at the University of California, San Francisco.  Her long-term mission is to help patients with end-stage liver disease survive to and thrive after liver transplantation.  Her primary research focuses on integrating core geriatric principles, such as frailty and physical function, into the day-to-day practice of hepatology and transplant medicine to improve the care of her patients.  She is the founder and principal investigator of the Functional Assessment in Liver Transplantation (FrAILT) Study, a multi-center collaboration aimed at investigating the impact of frailty on liver transplant outcomes.  For her work, she has been named a Beeson Scholar in Aging Research by the National Institute on Aging and a Top 40 Under 40 Leader by the San Francisco Business Times.

    Philip Rosenthal

    Michael F. Chang

    Josh Levitsky

    Josh Levitsky, MD, MS is currently a Professor of Medicine and Surgery in the Division of Gastroenterology & Hepatology at the Northwestern University Feinberg School of Medicine. Dr. Levitsky received his B.S. from the University of Michigan and M.D. from the Albert Einstein College of Medicine. He then completed an Internal Medicine residency and Gastroenterology fellowship at the University of Chicago Hospitals and a Transplant Hepatology fellowship at the University of Nebraska Medical Center, receiving an AASLD Fellowship Award. He is currently certified by the American Board of Internal Medicine in Gastroenterology and Transplant Hepatology. At Northwestern, he completed a Master of Science in Clinical Investigation, is the Director of Liver Research, and is the program director for both Gastroenterology and Transplant Hepatology Fellowships. He has been elected to the Northwestern Feinberg Academy of Medical Educators and has received several teaching awards.

    Dr. Levitsky is an active member of several professional societies, including the American Society of Transplantation and International Liver Transplantation Society where he served on the executive boards, as well as the AASLD where he has served on several committees. He is a Deputy Editor for the American Journal of Transplantation and on the Editorial Board for HEPATOLOGY. Dr. Levitsky’s academic interests are clinical and translational in nature, with a focus on liver transplant immunosuppression, tolerance and biomarkers. He previously received an AASLD Career Development Award in Liver Transplantation and has published numerous peer-reviewed journal articles, abstracts, book chapters and reviews on topics relevant to liver disease and transplantation. He is the principal and co-investigator for a number of NIH, pharmaceutical and investigator-initiated trials. His goal is to advance clinical/translational research in immune-mediated liver diseases and liver transplantation, identifying biomarkers and novel strategies to optimize outcomes.

    Robert J. Fontana

    Jacquelyn F. Fleckenstein

    Steven L. Flamm

    Scott W. Biggins

    Carl L. Berg

    Sandy Feng

    Norah A. Terrault

    Dr. Norah Terrault is the Professor of Medicine and the Director of the Viral Hepatitis Center at the University of California San Francisco. She is recognized nationally and internationally for her work related to viral hepatitis, especially in the setting of liver transplantation.  She has authored more than 290 original articles, reviews and book chapters on viral hepatitis, including the recent AASLD Hepatitis B Treatment Guidelines. She has served as associate editor for Hepatology, is current Associate Editor for Hepatology Communications and a member of the AASLD HCV Guidance Committee. She is an investigator on several NIH-funded clinical studies in hepatitis B and C, as well as NASH and is an investigator on several ongoing clinical trials of novel therapies for patients with chronic liver diseases.

     

     

    Peter Chin-Hong

    Michael D. Leise

    Dr. Leise finished his internal medicine residency, chief residency, Gastroenterology and Transplant Hepatology fellowships at Mayo Clinic, Rochester.  He is an Assistant Professor of Medicine with research interests in Hepatitis C, hepatic encephalopathy, and liver transplant outcomes.

    Mark W. Russo

    Philip Rosenthal

    Andrew I. Aronsohn

    Lisa VanWagner

    Dr. Lisa VanWagner is an Assistant Professor of Medicine and Preventive Medicine in the Division Gastroenterology & Hepatology at Northwestern University Feinberg School of Medicine in Chicago, Illinois.  She is board certified in Transplant Hepatology.  Her laboratory utilizes human population-based approaches, large electronic health record data analysis and health services research methods to define and characterize cardiovascular disease risk prediction, prevention and treatment approaches in patients with chronic liver disease.  Her research group developed the first simple scoring model (CAR-OLT score) — accessible via web or smartphone apps — which enables healthcare providers, caregivers and patients to estimate 1-year risk for cardiovascular complications after liver transplantation.

    Upon completion of this activity, learners will be able to: 

    • Discuss the diagnosis, natural history, and therapies for liver diseases leading to liver transplantation;
    • Discuss the management of patients awaiting liver transplantation;
    • Discuss the immediate post-operative and long-term management of liver transplant recipients;
    • Discuss current organ allocation policy and its effects on selecting potential liver transplant recipients.


    • Hepatologists
    • Fellows/ Trainees

    Satisfactory completion 

    Participants must pass a post-test with a score of 70% or higher and complete an evaluation to receive a certificate of completion.  If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement.   

    CME 

    Accreditation Statement The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Credit Designation AASLD designates this enduring activity for a maximum of 11.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

    Maintenance of Certification

    American Board of Internal Medicine (ABIM) MOC Statement 

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    American Board of Pediatrics (ABP) MOC Statement

    “Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn 11.0 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.”

    MOC Points Process

    Physicians seeking MOC points must complete the CME evaluation in addition to viewing all of the presentation(s) and successfully passing the post-test(s) for each module with a score of 70% or better. MOC completions are collected on the 15th of each month and submitted to the ABIM and/or ABP by the last day of the month.


    DISCLOSURE OF CONFLICTS OF INTEREST

    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

    The organizers and faculty have reported the following disclosures:

    Andrew I. Aronsohn, MD
    Faculty
    Nothing to Disclose

    Carl L. Berg, MD, FAASLD
    Faculty Scientific
    Consulting: Dova Pharnaceuticals, Grifols

    Scott W. Biggins, MD, MAS, FAASLD
    Faculty
    Nothing to Disclose

    Michael F. Chang, MD, MSc
    Faculty
    Nothing to Disclose

    Michael R. Charlton, MD, FRCP
    Faculty
    Grant/Research Support: Intercept, GIlead Sciences, Merck, Janssen, AbbVie, Novartis Scientific
    Consulting: Gilead Sciences

    Peter Chin-Hong, MD
    Faculty
    Grants/Research Support: Karius

    Sandy Feng, MD, PhD
    Faculty
    Stock/Stock Options: Abbott, Charles River Labs, Eli Lily, Express Scripts, Glaxo-Smith Klein, Medco, Merck, Pfizer, Hospira, Amgen, Johnson & Johnson, Stryker
    Advisory Committees and/or Review Panels: Juno Therapeutics, Inc., American Journal of Transplantation, Immune Tolderance Network, OPTN/UNOS, The New England Journal of Medicine
    Grants/Research Support: Novartis, Quark

    Oren K. Fix, MD, MSc, FAASLD
    Faculty
    Nothing to Disclose

    Steven L. Flamm, MD
    Faculty
    Nothing to Disclose

    Jacquelyn F. Fleckenstein, MD, FAASLD
    Faculty
    Nothing to Disclose

    Robert J. Fontana, MD, FAASLD
    Faculty
    Scientific Consulting: Alynam Pharmaceuticals
    Grants/Research Support: BMS, Gilead, Abbvie

    Julie Heimbach, MD, FAASLD
    Faculty
    Nothing to Disclose

    Laura M. Kulik, MD
    Faculty
    Nothing to Disclose

    Jennifer C. Lai, MD
    Faculty
    Scientific Consulting: Third Rock Ventures, LLC

    Michael D. Leise, MD
    Faculty
    Nothing to Disclose

    Josh Levitsky, MD, FAASLD
    Faculty
    Grants/Research Support: Novartis Scientific
    Consulting: Novartis
    Speakers Bureau: Gilead, Salix

    Michael R. Lucey, MD, FAASLD 
    Faculty
    Grant/Research Support: Abbvie, Gilead, Pharmasoluions

    Jorge A. Marrero, MD
    Faculty
    Scientific Consulting: Eisai, Grail, Exelis, Astra Zeneca

    K. Gautham Reddy, MD, FAASLD
    Faculty
    Grants/Research Support: Merck, Intercept, Genfit
    Scientific Consulting: Intercept
    Speaker's Bureau: Intercept Dova Advisory
    Committees and/or Review Panels: American College of Gastroenterology

    Philip Rosenthal, MD, FAASLD
    Faculty
    Grants/Research Support: Gilead Scientific
    Consulting: Gilead, Retrophin, Albireo

    Mark W. Russo, MD, MPH, FAASLD
    Faculty
    Speakers Bureau: Gilead, Abbvie, Intercept, Salix

    Marina G. Silveira, MD  
    Faculty
    Scientific Consulting: Conatus

    Norah Terrault, MD, MPH, FAASLD
    Faculty
    Scientific Consulting: CME, CCO Hepatitis, Practice Point Communications, Focus Medical Communications, Med IQ, PRIME Education Inc.
    Advisory Committees or Review Panels: Merck, Intercept, Conatus, Dova
    Grant/Research Support: AbbVie, Eisai, Gilead, BMS, Merck, Allergan, Biotest
    Royalties: UpToDate

    Lisa B. VanWagner, MD, MSc
    Faculty
    Grants/Research Support: Advanced MR Analytics (AMRA) Medical

    Maintenance of Certification Committee

    Oren K. Fix, MD, MSc, FAASLD
    Chair
    Nothing to disclose

    Mark W. Russo, MD, MPH, FAASLD
    Vice-Chair
    Commercial Speaker's Bureau: Gilead, Abbvie,Intercept, Salix

    Raymond T. Chung, MD, FAASLD
    Board Liaison
    Research Grants: Abbvie, Gilead Sciences, Boehringer Ingelheim

    Curtis K. Argo, MD, MS, FAASLD
    Member
    Nothing to disclose

    Steven K. Herrine, MD, FAASLD
    Member
    Research Grants: Gilead, BMS, Galectin, Interecept 
    Leadership in related society: Board, Committee, Journal: ABIM - Chair, Transplant Hepatology Test Committee

    Vandana Khungar, MD, MSc
    Member
    Nothing to disclose

    Ayman A. Koteish, MD, FAASLD
    Member
    Nothing to disclose

    Smruti R. Mohanty, MD, MS
    Member
    Advisory Board: Gilead science, Abbvie, Merck, Bristol Meyers Squib and Intercept
    Leadership in related society: Board, Committee, Journal: Publications Committee, American College of Gastroenterology (2009- Present) Education Committee Member, the Alliance for Academic Internal Medicine (AAIM) (July 2016-19) Editorial Board, World Journal of Gastroenterology (2007-Present) Editorial Board, Digestive Disease & Science (2009-Present) Editorial Board, World Journal of Hepatology

    Heather M. Patton, MD, FAASLD
    Member
    Nothing to disclose

    K. Gautham Reddy, MD, FAASLD
    Member
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Intercept, Gilead
    Research Grants: Merck Intercept Genfit
    Commercial Speaker's Bureau: Intercept
    Leadership in related society: Board, Committee, Journal: Member, Training Committee: American College of;

    Grace L. Su, MD, FAASLD
    Member
    Company: Management Position

    Ryan M. Taylor, MD
    Member
    Commercial Speaker's Bureau: Merck, Inc., Abbvie, Inc., Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Bristol-Myers Squibb

    Helen S. Te, MD, FAASLD
    Member
    Research Grants: Conatus Pharmaceuticals, Abbvie, Gilead Sciences
    Advisory Board: Gilead Sciences,Intercept Pharmaceuticals

    Debra Guss, RN, NP-C, ACRN
    Associate
    Nothing to disclose

    Katie Duggan, BA
    Staff Liaison
    Nothing to disclose

    Training and Workforce Committee

    K. Gautham Reddy, MD, FAASLD
    Chair
    Leadership in related society: Board, Committee, Journal: Member, Training Committee: American College of Gastoneterology;
    Research Grants: Merck Intercept Genfit; Commercial Speaker's Bureau: Intercept Dova; Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Intercept

    Raymond T. Chung, MD, FAASLD
    Board Liaison
    Research Grants: BMS, Roche,Gilead Sciences, Abbvie, Boehringer Ingelheim

    Christopher L. Bowlus, MD, FAASLD
    Member
    Research Grants: Gilead Biosciences, Intercept Pharmaceuticals, CymaBay Pharmaceuticals, Takeda Pharmaceuticals, NGM Biosciences, GlaxoSmithKline, Merck, BristolMyerSquibb, TARGET Pharmasolutions, Genkyotex, Allergan, JKB Taiwan Pharmaceuticals
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Intercept Pharmaceuticals, GlaxoSmithKline, BristolMyersSquibb, Conatus, Patara, Eli Lilly

    Michael F. Chang, MD, MSc, FAASLD
    Member
    Nothing to disclose

    Hari S. Conjeevaram, MD, MS
    Member
    Nothing to disclose

    Amy Feldman, MD
    Member
    Nothing to disclose

    Aparna Goel, MD
    Member
    Nothing to disclose

    Seth J. Karp, MD
    Member
    Nothing to disclose

    Michael D. Leise, MD
    Member
    Nothing to disclose

    Sylvia M. Lempit, MSN
    Associate Member
    Nothing to disclose

    Michelle Long, MD
    Member
    Research Grants: Echosens

    Ian R. Schreibman, MD
    Member
    Nothing to disclose

    Jessica Davis, MD
    Trainee
    Nothing to disclose

    Omar Y. Mousa, MD
    Trainee
    Nothing to disclose

    Katie Duggan, BA
    Staff Liaison
    Nothing to disclose

    Janeil Klett
    Staff Liaison
    Nothing to disclose

  • Cardiac Risk in Liver Transplantation: Getting to the “Heart” of the Matter

    Contains 1 Component(s) Recorded On: 09/10/2018

    Webinar hosted by the Cardiopulmonary Affinity group September 10, 2018.

    The overall objective of this activity is to address the epidemiology, risk factors and key challenges in the evaluation and management of cardiovascular disease in liver transplant candidates. In particular, we will discuss the evolving role of cirrhotic cardiomyopathy as a marker of ongoing cardiac injury.  

    Lisa VanWagner (Moderator)

    Dr. Lisa VanWagner is an Assistant Professor of Medicine and Preventive Medicine in the Division Gastroenterology & Hepatology at Northwestern University Feinberg School of Medicine in Chicago, Illinois.  She is board certified in Transplant Hepatology.  Her laboratory utilizes human population-based approaches, large electronic health record data analysis and health services research methods to define and characterize cardiovascular disease risk prediction, prevention and treatment approaches in patients with chronic liver disease.  Her research group developed the first simple scoring model (CAR-OLT score) — accessible via web or smartphone apps — which enables healthcare providers, caregivers and patients to estimate 1-year risk for cardiovascular complications after liver transplantation.

    Sam Lee (Moderator)

    Mario Altieri

    Dr. Mario Altieri is currently the medical director of the liver transplant program at the University Hospital Center in Caen, France since November, 2012. He did his Fellowship in intensive care medicine and Fellowship in multiple organ transplantation (liver, kidney and pancreas) at Strasbourg University France Hospital, University Center Hospital  HUC. He was the Chief of residency in Internal Medicine Cordoba, Argentina (Specialist certified NUCA) and was professor in intensive care medicine catholic University of Cordoba from 2000 to 2002.

    Manhal Izzy

    Dr. Manhal Izzy is a transplant hepatologist and an assistant professor at Vanderbilt University School of Medicine. He is a member of the educational committee of the International Liver Transplantation Society (ILTS). His research focuses on cardiovascular outcomes in patients with liver disease.

  • Implications of the Hepatitis C Epidemic on Women & Children

    Contains 1 Component(s) Recorded On: 09/07/2018

    Webinar hosted by the Hepatitis C Special interest group September 7, 2018.

    Chronic hepatitis C infection remains a major public health burden with substantial morbidity and mortality. In this program, expert hepatologists will provide a state-of-the-art update on the evolving epidemiology, natural history, and evidence-based management of hepatitis C infection in women of child-bearing age, pregnancy, and children.

    Dawn S. Harrison (Moderator)

    Dawn S. Harrison is a Family Nurse Practitioner specializing in Gastroenterology and Hepatology at The University of North Carolina Medical Center, Chapel Hill, North Carolina. She completed her Bachelor's of Science degree in Nursing from Radford University in Radford, Virginia and then earned her Master's of Science in Nursing as a Family Nurse Practitioner at Graceland University in Independence, Missouri.  Her Doctoral of Nursing Practice degree was acquired from The University of Alabama in Tusculoosa, Alabama. She holds a national certification with the American Nurses Credentialing Center (ANCC) as Family Nurse Practitioner. 

    Joseph K. Lim (Moderator)

    Joseph K. Lim, MD, FAASLD is a Professor of Medicine in the Section of Digestive Diseases and Yale Liver Center at Yale University School of Medicine in New Haven, CT where he serves as Director of the Viral Hepatitis Program.  He runs an active outcomes research and clinical trials program addressing viral hepatitis and fatty liver disease.  He is a member of the steering committee for the AASLD HCV SIG.

     

    Nancy S. Reau

    Dr. Nancy Reau is currently Associate Director of Solid Organ Transplantation and Section Chief of Hepatology at Rush University Medical Center. Dr Reau’s research interest is in viral hepatitis drug development as well as utilisation. She has authored or co-authored over 100 peer-reviewed articles, invited reviews, editorials and online programmes, as well as several book chapters, and two books. She is the editor in chief for Clinical Liver Disease, the AASLD multimedia journal.  She was one of the original authors of the AASLD/IDSA hepatitis C guidance document.  She is currently a member of the steering committee for the hepatitis C special interest group for the AASLD and is a member of the gastroenterology writing committee for the American Board of Internal Medicine.

     

    Tatyana Kushner

    Tatyana Kushner, MD, MSCE, is Assistant Professor in the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai in New York. She completed her medical school and internal medicine training at Mount Sinai School of Medicine, a fellowship in gastroenterology and a masters in clinical epidemiology at the University of Pennsylvania, and a fellowship in transplant hepatology at the University of California, San Francisco (UCSF). Her research focuses on both epidemiologic and patient-centered outcomes in viral hepatitis, with an emerging focus in the area of women’s health and pregnancy care, and the goal of developing and studying interventions to improve clinical outcomes in this patient population. She has recently established a Women's Liver Clinic at Mount Sinai in order to enhance the diagnosis and management of liver disease during pregnancy and post-delivery, particularly of hepatitis B and hepatitis C. 

     

    Karen Murray

    Dr. Karen Murray is board certified in pediatric gastroenterology and pediatric transplant hepatology. In addition to providing clinical care in gastroenterology, hepatology and transplantation, she has an active clinical research program. Her main focus is childhood liver disease, especially the treatment of hepatitis B and C viral infections, non-alcoholic fatty liver disease and cholestatic liver diseases in childhood. Murray is a professor of pediatrics at University of Washington School of Medicine and past president of Seattle Children’s medical staff. She is on the steering committees of three National Institute of Diabetes and Digestive and Kidney Diseases clinical research networks related to her research.

  • Unraveling the New UNOS Liver Allocation Policy

    Contains 1 Component(s) Recorded On: 09/04/2018

    Webinar hosted by the Liver Transplantation and Surgery Special Interest Group and Liver Transplantation Journal September 4, 2018.

    The new UNOS organ allocation policy is scheduled to go into effect in December 2018. Work your way through the changes and challenges with the Chair of the AASLD Liver Transplantation SIG and Editor-in-Chief of Liver Transplantation in this first of a series of webinars brought to you by a collaboration of the SIG and journal. 

    Paul Martin (Moderator)

    Paul Martin MD, FAASLD is Professor of Medicine and Chief of the Divisions of Gastroenterology and Hepatology at the University of Miami, USA. He is a native of Dublin, Ireland, where he graduated from medical school at University College, Dublin. He specialized in internal medicine and gastroenterology, training initially in Dublin and subsequently in Canada. He trained in hepatology as a Medical Staff Fellow in the Liver Unit, NIH, Maryland, USA. He is Editor-in Chief of Liver Transplantation and Editor of Handbook of Liver Disease. He was previously a Councilor for AST of the American Society of Transplant. He has had a long standing interest in viral hepatitis and organ transplant. 

    Timucin Taner

    Dr. Taner is a transplant surgeon, and surgical director of liver transplantation at Mayo Clinic, Rochester. He is a member of the AASLD Surgery and Liver Transplantation Committee, and currently serves as the chair of the Liver Transplantation SIG Education Subcommittee.

    James Trotter

    Dr. James Trotter is currently the medical director of liver transplantation at Baylor University Medical Center. He is also the principal investigator of the Living donor liver transplant Cohort Study at the National Institutes of Health. Dr. Trotter is the associate editor of the Liver Transplantation journal.